Novel therapy brings hope in neuroendocrine tumors : Lutetium-177 (Lu-177) peptide receptor radionuclide therapy (PRRT) is showing significant promise in the treatment of patients with inoperable or metastasized neuroendocrine tumors.

Novel therapy brings hope in neuroendocrine tumors:

Award-winning researchers from a top London facility have demonstrated how...



Read more on AuntMinnieEurope.com



Related Reading:

FDA approves new radionuclide therapy by AAA

FDG-PET adds to gallium-68 scans for neuroendocrine tumors

First choice for neuroendocrine tumors: Ga-68 DOTATATE

Ga-68 DOTATATE PET/CT detects neuroendocrine tumor recurrence

Ga-68 DOTATOC PET/MRI tops PET/CT for staging neuroendocrine tumors

Original enclosures:

2019_12_13_19_51_1879_carcinoid_neuroendocrine_tumor_400.jpg